|
n
|
PD-L1 expression
|
PD-1 expression
|
---|
Cancerous cell (+)
|
p value
|
Stromal cells (+)
|
p value
|
Lymphocyte (+)
|
p value
|
---|
Tumor size, cm
| | |
0.806
| |
0.9
| |
0.034
|
> 5 cm
|
33
|
3 (9.1%)
| |
17 (51.5%)
| |
6 (18.2%)
| |
≤ 5 cm
|
36
|
5 (13.9%)
| |
18 (50%)
| |
15 (41.7%)
| |
Tumor number
| | |
0.812
| |
0.348
| |
0.499
|
Single
|
54
|
6 (11.1%)
| |
29 (53.7%)
| |
18 (33.3%)
| |
Multiple
|
15
|
2 (13.3%)
| |
6 (40%)
| |
3 (20%)
| |
Gross types
| | |
0.186
| |
0.348
| |
0.22
|
MF
|
54
|
8 (14.8%)
| |
29 (53.7%)
| |
14 (25.9%)
| |
Non-MF
|
15
|
0 (0)
| |
6 (40%)
| |
7 (46.7%)
| |
Differentiation
| | |
0.043
| |
0.308
| |
0.408
|
Well
| |
0 (0)
| |
1 (2.8%)
| |
1 (4.8%)
| |
Moderately
| |
5 (63%)
| |
29 (82.9%)
| |
19 (90.4%)
| |
Poorly or undifferentiated
| |
3 (37%)
| |
5 (14.3%)
| |
1 (4.8%)
| |
CLC or cICC
|
14
|
3 (21.4%)
|
0.412
|
9 (64.3%)
|
0.256
|
3 (21.4%)
|
0.621
|
MVI
|
25
|
4 (16%)
|
0.638
|
0 (0)
|
0.199
|
4 (16%)
|
0.005
|
Neural invasion
|
69
|
8 (11.6%)
|
0.227
|
35 (50.7%)
|
0.988
|
21 (30.4%)
|
1.0
|
TNM stage
| | |
0.245
| |
0.429
| |
0.282
|
I
|
28
|
1 (3.6%)
| |
6 (21.4%)
| |
8 (28.6%)
| |
II
|
25
|
5 (20%)
| |
13 (52%)
| |
6 (24%)
| |
III
|
5
|
1 (20%)
| |
2 (40%)
| |
1 (20%)
| |
IV
|
11
|
1 (9.1%)
| |
6 (54.5%)
| |
6 (54.5%)
| |
Breakthrough the liver
|
12
|
1 (8.3%)
|
0.698
|
6 (50%)
|
0.956
|
3 (25%)
|
0.916
|
Grade of inflammation
| | |
0.961
| |
0.504
| |
0.853
|
G0,G1or G2
|
60
|
7 (11.7%)
| |
29 (48.3%)
| |
19 (31.7%)
| |
G3 or G4
|
9
|
1 (11.1%)
| |
6 (66.7%)
| |
2 (22.2%)
| |
Fibrosis/cirrhosis
| | |
0.012
| |
0.77
| |
0.686
|
S0,S1 or S2
|
59
|
4 (6.78%)
| |
29 (49.2%)
| |
19 (32.2%)
| |
(S3 or S4)
|
10
|
4 (40%)
| |
6 (60%)
| |
2 (20%)
| |
CD8 density/Hp
|
CD8+ TIL ≥ 40
|
4
|
4 (100%)
|
< 0.0001
|
4 (100%)
| |
1 (25%)
| |
CD8+ NIL ≥ 40
|
19
|
6 (31.6%)
|
< 0.0001
|
13 (68.4%)
| |
8 (42.1%)
| |
- MF mass-forming, CLC Cholangiolocellular Carcinoma, cICCconventional Intrahepatic Cholangiocarcinoma, MVI microvascular invasion